Tissue factor pathway-related biomarkers in liver cancer: activated factor VII–antithrombin complex and tissue factor mRNA levels are associated with mortality

• Published in: Research and practice in thrombosis and haemostasis Vol. 8; no. 1; p. 102310
• Main Authors: Martinelli, Nicola, Moruzzi, Sara, Udali, Silvia, Castagna, Annalisa, Di Santo, Laura, Ambrosani, Francesca, Baroni, Marcello, Pattini, Patrizia, Pizzolo, Francesca, Ruzzenente, Andrea, Conci, Simone, Grusse, Matthieu, Campagnaro, Tommaso, Van Dreden, Patrick, Guglielmi, Alfredo, Bernardi, Francesco, Olivieri, Oliviero, Friso, Simonetta
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2024
• Subjects: activated factor VII–antithrombin; cholangiocarcinoma; hepatocellular carcinoma; prognosis; tissue factor mRNA expression; activated factor VII–antithrombin; cholangiocarcinoma; prognosis; tissue factor mRNA expression; hepatocellular carcinoma
• ISSN: 2475-0379; 2475-0379
• DOI: 10.1016/j.rpth.2023.102310

Tissue factor (TF), the main initiator of the coagulation cascade, plays a role in cancer progression and prognosis. Activated factor VII–antithrombin complex (FVIIa-AT) is considered an indirect marker of TF exposure by reflecting TF-FVIIa interaction. To assess the link between FVIIa-AT plasma levels, TF messenger RNA (mRNA) expression, and survival in cancer. TF pathway–related coagulation biomarkers were assessed in 136 patients with cancer (52 with hepatocellular carcinoma, 41 with cholangiocarcinoma, and 43 with colon cancer) undergoing surgical intervention with curative intent. TF mRNA expression analysis in neoplastic vs nonneoplastic liver tissues was evaluated in a subgroup of 91 patients with primary liver cancer. FVIIa-AT levels were higher in patients with cancer than in 136 sex- and age-matched cancer-free controls. In patients with cancer, high levels of FVIIa-AT and total TF pathway inhibitor were associated with an increased mortality risk after adjustment for confounders, but only FVIIa-AT remained a predictor of mortality by including both FVIIa-AT and total TF pathway inhibitor in Cox regression (hazard ratio, 2.80; 95% CI, 1.23-6.39; the highest vs the lowest quartile). This association remained significant even after adjustment for extracellular vesicle–associated TF-dependent procoagulant activity. In the subgroup of patients with primary liver cancer, patients with high TF mRNA levels had an increased mortality risk compared with that for those with low TF mRNA levels (hazard ratio, 1.92; 95% CI, 1.03-3.57), and there was a consistent correlation among high FVIIa-AT levels, high TF mRNA levels, and increased risk of mortality. High FVIIa-AT levels may allow the identification of patients with cancer involving high TF expression and predict a higher mortality risk in liver cancer. •Activated factor (F)VII–antithrombin (FVIIa-AT) complex is an indirect marker of tissue factor (TF) activity.•FVIIa-AT plasma levels and TF messenger RNA (mRNA) levels in liver tissues were assessed for liver cancer.•Subjects with high TF mRNA levels in cancer tissues had an increased risk of mortality.•High FVIIa-AT levels were associated with both high TF mRNA levels and increased risk of mortality.